Aquestive Therapeutics, Inc. - FORM S-1/A - EX-23.1 - EXHIBIT 23.1 - July 16, 2018

Attached files

file filename
EX-10.15 - EXHIBIT 10.15 - Aquestive Therapeutics, Inc.s002128x7_ex10-15.htm
EX-10.18 - EXHIBIT 10.18 - Aquestive Therapeutics, Inc.s002128x7_ex10-18.htm
EX-10.17 - EXHIBIT 10.17 - Aquestive Therapeutics, Inc.s002128x7_ex10-17.htm
EX-10.14 - EXHIBIT 10.14 - Aquestive Therapeutics, Inc.s002128x7_ex10-14.htm
EX-10.10 - EXHIBIT 10.10 - Aquestive Therapeutics, Inc.s002128x7_ex10-10.htm
EX-10.9 - EXHIBIT 10.9 - Aquestive Therapeutics, Inc.s002128x7_ex10-9.htm
EX-10.8 - EXHIBIT 10.8 - Aquestive Therapeutics, Inc.s002128x7_ex10-8.htm
EX-10.5 - EXHIBIT 10.5 - Aquestive Therapeutics, Inc.s002128x7_ex10-5.htm
EX-5.1 - EXHIBIT 5.1 - Aquestive Therapeutics, Inc.s002128x7_ex5-1.htm
EX-3.3 - EXHIBIT 3.3 - Aquestive Therapeutics, Inc.s002128x7_ex3-3.htm
EX-1.1 - EXHIBIT 1.1 - Aquestive Therapeutics, Inc.s002128x7_ex1-1.htm
S-1/A - S-1/A - Aquestive Therapeutics, Inc.s002128x7_s1a.htm

Exhibit 23.1
 
Consent of Independent Registered Public Accounting Firm
 
The Board of Directors
 Aquestive Therapeutics, Inc.:
 
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP
 
New York, New York
 July 15, 2018
 
 

Aquestive Therapeutics, Inc. Reports